Rituximab
- Generic Name
- Rituximab
- Brand Names
- MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 174722-31-7
- Unique Ingredient Identifier
- 4F4X42SYQ6
- Background
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...
- Indication
Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...
- Associated Conditions
- Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)
- Associated Therapies
- -
Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT05896007
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
- Conditions
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 30
- Registration Number
- NCT05887726
- Locations
- 🇨🇳
Xing Xiaojing, Shenyang, Liaoning, China
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT05886036
- Locations
- 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of Kansas Cancer Center, Kansas City, Kansas, United States
A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Istituto Clinico Humanitas
- Target Recruit Count
- 20
- Registration Number
- NCT05877040
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milano, Italy
Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-06-07
- Target Recruit Count
- 40
- Registration Number
- NCT05868837
- Locations
- 🇮🇹
Policlinico A. Gemelli IRCCS, Roma, Italy
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Registration Number
- NCT05867030
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 40
- Registration Number
- NCT05864742
- Locations
- 🇦🇺
Flinders Medical Centre, Bedford Park, South Australia, Australia
🇦🇺Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Immune Thrombocytopenia Management in Adults
- Conditions
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Nahda University
- Target Recruit Count
- 467
- Registration Number
- NCT05861297
- Locations
- 🇪🇬
EL-Kasr elineiy, Cairo, Egypt
Rituximab in the First Episode of Paediatric Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Children's Hospital of Fudan University
- Target Recruit Count
- 138
- Registration Number
- NCT05850546
- Locations
- 🇨🇳
Children's hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Shanghai's Children's Medical Center, Shanghai, Shanghai, China
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
- Conditions
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 284
- Registration Number
- NCT05848765
- Locations
- 🇬🇧
Cardiff and vale University LHB, Cardiff, United Kingdom
🇬🇧Belfast Health & Social Care Trust, Belfast, United Kingdom
🇬🇧NHS Grampian, Aberdeen, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.